Form 4: Invivyd CLO Sells Shares Post-RSU Vesting
Insider Transaction Report
Invivyd's Chief Legal Officer, Jill Andersen, sold shares to cover tax obligations following the vesting of restricted stock units.
Summary
- Jill Andersen, Invivyd's Chief Legal Officer and Secretary, reported transactions related to her equity holdings.
- On August 15, 2025, 165,000 restricted stock units (RSUs) vested, converting into common stock.
- Following the vesting, Andersen sold 33,352 shares on August 18, 2025, at a weighted average price of $0.6502, with prices ranging from $0.5801 to $0.7134.
- An additional 49,402 shares were sold on August 19, 2025, at a weighted average price of $0.5666, with prices ranging from $0.5524 to $0.6040.
- These sales were non-discretionary "sell-to-cover" transactions executed under a Rule 10b5-1 plan adopted on February 20, 2025, to satisfy tax withholding obligations.
- After these transactions, Andersen directly holds 84,446 common shares and indirectly holds 500 shares through her spouse.
- Andersen also holds 335,000 unvested Restricted Stock Units.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While there are sales by an insider, they are non-discretionary 'sell-to-cover' transactions for tax purposes, which is a routine event following RSU vesting. The vesting itself is a positive for the executive and indicates compensation milestones are being met. The declining price during the sales is a minor negative.
Positives
- Vesting of 165,000 Restricted Stock Units indicates a milestone in the compensation plan for the Chief Legal Officer.
- The sales were pre-planned under a Rule 10b5-1 plan, indicating a structured approach to managing equity compensation and tax obligations.
Negatives
- The sales represent a reduction in direct beneficial ownership by a key executive.
- The weighted average sale price on August 19, 2025 ($0.5666), was lower than the sale price on August 18, 2025 ($0.6502), indicating a declining share price during the sale period.
Future Outlook
The remaining 335,000 Restricted Stock Units are scheduled to vest over an eighteen-month period, with one-third vesting every six months following the February 15, 2025 grant date, subject to continuous service.
Industry Context
This filing is a routine disclosure of insider transactions, common across all publicly traded companies, and does not provide specific insights into broader industry trends for the biotechnology or pharmaceutical sector. It reflects an executive's management of their equity compensation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Jill Andersen granted a Limited Power of Attorney to six individuals (William E. Duke, Katherine Fisher, Kiernan Decker, Stephen Nicolai, Steve Abrams, Amanda Brown) to handle her Section 16 and Rule 144 reporting obligations (Forms 3, 4, 5, and 144) and EDGAR account administration. This is a standard practice to ensure timely and compliant filings. | 2025-08-13 | Enhances efficiency and compliance for executive's SEC reporting requirements, reducing administrative burden on the executive and ensuring adherence to regulatory deadlines. |
Related Party Transactions
- The reported stock sales by Jill Andersen, a Chief Legal Officer, are considered related-party transactions as they involve an executive and the company's securities. These were specifically "sell-to-cover" transactions for tax obligations following RSU vesting.
Stakeholder Impact
- Shareholders: The sale of shares by an executive, even for tax purposes, slightly increases the float and could be perceived as a minor negative signal, though the pre-planned nature mitigates this. The vesting of RSUs indicates executive retention and alignment with company performance.
- Employees: The RSU vesting and subsequent tax-related sales are typical for equity compensation plans, providing a clear example of how such plans operate for executives.
Next Steps
- Future vesting of the remaining 335,000 Restricted Stock Units, with one-third vesting every six months following February 15, 2025.
Key Dates
| Date | Description |
|---|---|
| 2025-02-15 | Grant date of the RSU award, with vesting over an eighteen-month period. |
| 2025-02-20 | Date Rule 10b5-1 plan was adopted by Jill Andersen. |
| 2025-08-13 | Date Limited Power of Attorney was executed by Jill Andersen. |
| 2025-08-15 | Date of RSU vesting and acquisition of 165,000 common shares. |
| 2025-08-18 | Date of sale of 33,352 common shares. |
| 2025-08-19 | Date of sale of 49,402 common shares and filing date of Form 4. |
Recommendation
holdThis Form 4 filing details routine, non-discretionary "sell-to-cover" transactions by a company executive to satisfy tax obligations upon RSU vesting. Such transactions are pre-planned under a Rule 10b5-1 plan and do not typically signal a change in the executive's outlook on the company's future performance. While the sales reduce the executive's direct holdings, the underlying RSU vesting is a positive compensation event. The filing provides no new fundamental information about the company's operations, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a "hold" recommendation is appropriate as this is a neutral event from an investment decision perspective.
Keywords
Invivyd, IVVD, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Rule 10b5-1, Executive Compensation, Jill Andersen, Chief Legal Officer, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.